ADRP Advisory Board Member Amanda Hess discusses advances in transfusion medicine, challenges blood centers face, and how ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Will fund a pilot study to analyze longitudinal plasma samples covering a period of up to 10 years.

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest's fibrinogen aims to fulfill a high unmet medical need for ...

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Spanish plasma-based medicines maker Grifols (MCE: GRF) has announced disappointing top-line data from its Phase III PRECIOSA clinical trial evaluating the potential of long-term albumin treatment ...

US short seller Gotham City Research asked a judge in New York to dismiss a lawsuit accusing it of conspiring to drive down shares in Grifols SA. The drug maker’s market capitalization has ...

However, it’s not as easy as it sounds. For a fusion reaction, plasma is required to be heated to hundreds of millions of degrees Celsius — this is seven to eight times more than the ...